Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai Anti-Arrhythmic Agent Tambocor Receives Approval In Japan
Eisai said that as there are currently few anti-arrhythmic agents with limited indications approved for pediatric use in Japan, arrhythmia has represented an area of unmet medical need
Eisai said that as there are currently few anti-arrhythmic agents with limited indications approved for pediatric use in Japan, arrhythmia has represented an area of unmet medical need
Beximco Pharma has posted a net profit of $.21m for the first quarter 2010, or $1.3 earnings per share (EPS), compared to $.12m, or $0.82 EPS, for the
Rosuvastatin calcium is indicated for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia) and falls under the CardioVascular (CVS) therapeutic category. Aurobindo Pharma
Repligen said that the study is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up
Novavax said that it has produced a 2009 H1N1 influenza VLP vaccine and delivered it to the CDC in less than four weeks following the April 24, 2009
The locations further expand Parexel’s presence in China, which includes offices in Beijing and Shanghai as well as Kowloon, Hong Kong. Parexel now has 17 biopharmaceutical centres in
Specifically, in a pig model, subjects with deep tissue wounds that were administered 200mcgs of Vitaros healed four times faster than those receiving placebo over a 21-day period.
Boston Scientific Taxus Element Stent System incorporates a platinum chromium alloy with a new stent design and an advanced catheter delivery system. The company plans to launch the
As per the terms of the agreement, Pfizer will support the completion of the ongoing Phase 2 trial for Terguride and will have exclusive worldwide rights excluding Japan
Bioject Medical has reported a first quarter 2010 net loss allocable to common shareholders of $568,000 compared to net loss allocable to common shareholders of $237,000 in the